Get the Stockscreener App
1.735
1.42%
-0.025
Nervgen Pharma Corp stock is traded at $1.735, with a volume of 562.01K.
It is down -1.42% in the last 24 hours and down -0.29% over the past month.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$1.76
Open:
$1.78
24h Volume:
562.01K
Relative Volume:
0.61
Market Cap:
$184.63M
Revenue:
-
Net Income/Loss:
$-31.64M
P/E Ratio:
-4.1055
EPS:
-0.4226
Net Cash Flow:
$-13.98M
1W Performance:
+1.46%
1M Performance:
-0.29%
6M Performance:
-58.89%
1Y Performance:
+0.00%
1-Day Range:
$1.655
$1.78
1-Week Range:
$1.655
$1.82
52-Week Range:
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.735 | 187.29M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals Market Sentiment - benzinga.com
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NGEN Q3 2025 Earnings: Slight EPS Beat Amid Ongoing Pipeline DevelopmentGAAP Earnings Report - dars.gov.et
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
H.C. Wainwright cuts NervGen stock price target to $15 on dilution By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Nigeria
NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key SupportRelative Volume - dars.gov.et
NGEN Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - Moomoo
NervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink Partners - MarketBeat
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Small EPS Beat as Pipeline Progress Underpins Market ConfidenceOperating Margin Analysis - dars.gov.et
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
NervGen Pharma Corp. (NGEN) Edges Higher: Biotech Stock Tests Support at $2.01 Amid Modest GainsDividend Arbitrage - dars.gov.et
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners - TipRanks
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
NGEN Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseProfit Recovery Report - dars.gov.et
NGEN Q3 2025 Earnings: Narrower Loss Surprises, Stock Advances Amid Pipeline FocusGeographic Revenue Trends - dars.gov.et
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBIT forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBITDA forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):